Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma

Brian T. Hill, Lisa Rybicki, Stephen Smith, Robert Dean, Matt Kalaycio, Brad Pohlman, John Sweetenham, Shawnda Tench, Ronald Sobecks, Steven Andresen, Edward Copelan, Brian J. Bolwell

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate) is an intense chemotherapy regimen frequently used for hematologic malignancies including mantle cell lymphoma. To address whether treatment with hyper-CVAD impairs mobilization of peripheral blood stem cells, we retrospectively analyzed mobilization data from 77 consecutive adult patients with mantle cell lymphoma who underwent peripheral blood stem cell (PBSC) mobilization for planned autologous stem cell transplant (ASCT). Compared to patients treated with alternative regimens, patients treated with hyper-CVAD collected fewer CD34+ cells, required more total days of pheresis, and more frequently required a second mobilization attempt, despite being more likely to have undergone mobilization with a VP16-containing regimen. In multivariable linear regression analysis, treatment with hyper-CVAD was associated with a significant reduction in total CD34+ cells mobilized (p < 0.001). These findings suggest that alternative mobilizing strategies prior to ASCT are needed for patients with mantle cell lymphoma who have received hyper-CVAD.

Original languageEnglish (US)
Pages (from-to)986-993
Number of pages8
JournalLeukemia and Lymphoma
Volume52
Issue number6
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Cytarabine
Vincristine
Methotrexate
Doxorubicin
Cyclophosphamide
Dexamethasone
Stem Cells
Hematopoietic Stem Cell Mobilization
Transplants
Blood Component Removal
Hematologic Neoplasms
Therapeutics
Linear Models
Regression Analysis
Drug Therapy
Peripheral Blood Stem Cells

Keywords

  • autologous stem cell transplant
  • hyper-CVAD
  • Mantle cell lymphoma
  • mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. / Hill, Brian T.; Rybicki, Lisa; Smith, Stephen; Dean, Robert; Kalaycio, Matt; Pohlman, Brad; Sweetenham, John; Tench, Shawnda; Sobecks, Ronald; Andresen, Steven; Copelan, Edward; Bolwell, Brian J.

In: Leukemia and Lymphoma, Vol. 52, No. 6, 01.06.2011, p. 986-993.

Research output: Contribution to journalArticle

Hill, Brian T. ; Rybicki, Lisa ; Smith, Stephen ; Dean, Robert ; Kalaycio, Matt ; Pohlman, Brad ; Sweetenham, John ; Tench, Shawnda ; Sobecks, Ronald ; Andresen, Steven ; Copelan, Edward ; Bolwell, Brian J. / Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 6. pp. 986-993.
@article{bf370394b7004dca8fcc19d96ca0be10,
title = "Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma",
abstract = "Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate) is an intense chemotherapy regimen frequently used for hematologic malignancies including mantle cell lymphoma. To address whether treatment with hyper-CVAD impairs mobilization of peripheral blood stem cells, we retrospectively analyzed mobilization data from 77 consecutive adult patients with mantle cell lymphoma who underwent peripheral blood stem cell (PBSC) mobilization for planned autologous stem cell transplant (ASCT). Compared to patients treated with alternative regimens, patients treated with hyper-CVAD collected fewer CD34+ cells, required more total days of pheresis, and more frequently required a second mobilization attempt, despite being more likely to have undergone mobilization with a VP16-containing regimen. In multivariable linear regression analysis, treatment with hyper-CVAD was associated with a significant reduction in total CD34+ cells mobilized (p < 0.001). These findings suggest that alternative mobilizing strategies prior to ASCT are needed for patients with mantle cell lymphoma who have received hyper-CVAD.",
keywords = "autologous stem cell transplant, hyper-CVAD, Mantle cell lymphoma, mobilization",
author = "Hill, {Brian T.} and Lisa Rybicki and Stephen Smith and Robert Dean and Matt Kalaycio and Brad Pohlman and John Sweetenham and Shawnda Tench and Ronald Sobecks and Steven Andresen and Edward Copelan and Bolwell, {Brian J.}",
year = "2011",
month = "6",
day = "1",
doi = "10.3109/10428194.2010.551154",
language = "English (US)",
volume = "52",
pages = "986--993",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma

AU - Hill, Brian T.

AU - Rybicki, Lisa

AU - Smith, Stephen

AU - Dean, Robert

AU - Kalaycio, Matt

AU - Pohlman, Brad

AU - Sweetenham, John

AU - Tench, Shawnda

AU - Sobecks, Ronald

AU - Andresen, Steven

AU - Copelan, Edward

AU - Bolwell, Brian J.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate) is an intense chemotherapy regimen frequently used for hematologic malignancies including mantle cell lymphoma. To address whether treatment with hyper-CVAD impairs mobilization of peripheral blood stem cells, we retrospectively analyzed mobilization data from 77 consecutive adult patients with mantle cell lymphoma who underwent peripheral blood stem cell (PBSC) mobilization for planned autologous stem cell transplant (ASCT). Compared to patients treated with alternative regimens, patients treated with hyper-CVAD collected fewer CD34+ cells, required more total days of pheresis, and more frequently required a second mobilization attempt, despite being more likely to have undergone mobilization with a VP16-containing regimen. In multivariable linear regression analysis, treatment with hyper-CVAD was associated with a significant reduction in total CD34+ cells mobilized (p < 0.001). These findings suggest that alternative mobilizing strategies prior to ASCT are needed for patients with mantle cell lymphoma who have received hyper-CVAD.

AB - Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate) is an intense chemotherapy regimen frequently used for hematologic malignancies including mantle cell lymphoma. To address whether treatment with hyper-CVAD impairs mobilization of peripheral blood stem cells, we retrospectively analyzed mobilization data from 77 consecutive adult patients with mantle cell lymphoma who underwent peripheral blood stem cell (PBSC) mobilization for planned autologous stem cell transplant (ASCT). Compared to patients treated with alternative regimens, patients treated with hyper-CVAD collected fewer CD34+ cells, required more total days of pheresis, and more frequently required a second mobilization attempt, despite being more likely to have undergone mobilization with a VP16-containing regimen. In multivariable linear regression analysis, treatment with hyper-CVAD was associated with a significant reduction in total CD34+ cells mobilized (p < 0.001). These findings suggest that alternative mobilizing strategies prior to ASCT are needed for patients with mantle cell lymphoma who have received hyper-CVAD.

KW - autologous stem cell transplant

KW - hyper-CVAD

KW - Mantle cell lymphoma

KW - mobilization

UR - http://www.scopus.com/inward/record.url?scp=79957510429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957510429&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.551154

DO - 10.3109/10428194.2010.551154

M3 - Article

C2 - 21314484

AN - SCOPUS:79957510429

VL - 52

SP - 986

EP - 993

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -